Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations

BMC Infectious Diseases

Jorge Quarleri³  Hugo Tanno¹  Fabian Fay²  Silvina Benetti²  Lucila Cassino³ 

[1]Servicio de Gastroenterología y Hepatología del Hospital Provincial de Centenario, Rosario, Argentina

[2]Centro de Diagnóstico Médico de Alta Complejidad (CIBIC), Rosario, Argentina

[3]Consejo Nacional de Investigaciones Científicas y Técnicas, Argentina

关键词: entecavir;    tenofovir;    resistance;    lamivudine;    hepatitis B virus;   

Others  :  1175671
DOI  :  10.1186/1471-2334-11-178

 received in 2010-12-17, accepted in 2011-06-22,  发布年份 2011

【 摘 要 】

Background

Complex mutants can be selected under sequential selective pressure by HBV therapy. To determine hepatitis B virus genomic evolution during antiviral therapy we characterized the HBV quasi-species in a patient who did no respond to therapy following lamivudine breakthrough for a period of 14 years.

Case Presentation

The polymerase and precore/core genes were amplified and sequenced at determined intervals in a period of 14 years. HBV viral load and HBeAg/Anti-HBe serological profiles as well as amino transferase levels were also measured. A mixture of lamivudine-resistant genotype A2 HBV strains harboring the rtM204V mutation coexisted in the patient following viral breakthrough to lamivudine. The L180M+M204V dominant mutant displayed strong lamivudine-resistance. As therapy was changed to adefovir, then to entecavir, and finally to entecavir-tenofovir the viral load showed fluctuations but lamivudine-resistant strains continued to be selected, with minor contributions to the HBV quasi-species composition of additional resistance-associated mutations. At the end of the 14-year follow up period, high viral loads were predominant, with viral strains harboring the lamivudine-resistance signature rtL180M+M204V. The precore/core frame A1762T and G1764A double mutation was detected before treatment and remaining in this condition during the entire follow-up. Specific entecavir and tenofovir primary resistance-associated mutations were not detected at any time. Plasma concentrations of tenofovir indicated adequate metabolism of the drug.

Conclusions

We report the selection of HBV mutants carrying well-defined primary resistance mutations that escaped lamivudine in a fourteen-year follow-up period. With the exception of tenofovir resistance mutations, subsequent unselected primary resistance mutations were detected as minor populations into the HBV quasispecies composition during adefovir or entecavir monotherapies. Although tenofovir is considered an appropriate therapeutic alternative for the treatment of entecavir-unresponsive patients, its use was not effective in the case reported here.

【 授权许可】

   
2011 Cassino et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 2.

【 参考文献 】

• [1]Lai M, Liaw YF: Chronic hepatitis B: past, present, and future. Clin Liver Dis 2010, 14(3):531-46.
• [2]Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D, BEHoLD AI463022 Study Group: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006, 354(10):1001-10.
• [3]Chan HL, Wang H, Niu J, Chim AM, Sung JJ: Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther 2007, 12(3):345-53.
• [4]Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J, Cirrhosis Asian Lamivudine Multicentre Study Group: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351:1521-1531.
• [5]Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL: Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000, 119:172-180.
• [6]Gallego A, Sheldon J, García-Samaniego J, Margall N, Romero M, Hornillos P, Soriano V, Enrĺquez J: Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B. J Viral Hepat 2008, 15(5):392-8.
• [7]Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz A, Locarnini S: Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003, 125(2):292-7.
• [8]Gonzalez SA, Keeffe EB: Entecavir for the long-term treatment of chronic hepatitis B. Expert Rev Anti Infect Ther 2009, 7(9):1053-62.
• [9]Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J, Kreter B, Hindes R, AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study Group: Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008, 48(1):99-108.
• [10]Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH, Chao YC, Lee SD, Harris M, Yang J, Colonno R, Brett-Smith H: Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007, 133(5):1437-44.
• [11]Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, Pastore G, Bacon BR, Poynard T, Joshi S, Klesczewski KS, Thiry A, Rose RE, Colonno RJ, Hindes RG, BEHoLD Study Group: A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005, 129:1198-1209.
• [12]Tenney DJ: Genotypic determinants and phenotypic properties of antiviral-resistant HBV variants: insight from entecavir resistance studies. Antivir Ther 2010, 15(3 Pt B):529-35.
• [13]Tillmann HL: Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol 2007, 13(1):125-40.
• [14]Seifer M, Patty A, Serra I, Li B, Standring DN: Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir. Antiviral Res 2009, 81(2):147-55.
• [15]de Vries-Sluijs TE, van der Eijk AA, Hansen BE, Osterhaus AD, de Man RA, van der Ende ME: Wild type and YMDD variant of hepatitis B virus: no difference in viral kinetics on lamivudine/tenofovir therapy in HIV-HBV co-infected patients. J Clin Virol 2006, 36:60-63.
• [16]van Bömmel F, Wünsche T, Mauss S, Reinke P, Bergk A, Schürmann D, Wiedenmann B, Berg T: Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004, 40:1421-1425.
• [17]de Vries-Sluijs TE, Reijnders JG, Hansen BE, Zaaijer HL, Prins JM, Pas SD, Schutten M, Hoepelman AI, Richter C, Mulder JW, de Man RA, Janssen HL, van der Ende ME: Long-Term Therapy With Tenofovir Is Effective for Patients Co-Infected With Human Immunodeficiency Virus and Hepatitis B Virus. Gastroenterology 2010, 139(6):1934-41.
• [18]Gordillo RM, Gutiérrez J, Casal M: Evaluation of the COBAS TaqMan 48 real-time PCR system for quantitation of hepatitis B virus DNA. J Clin Microbiol 2005, 43(7):3504-7.
• [19]Cassino L, Laufer N, Salomon H, Campos R, Quarleri J: Hepatitis B precore/core promoter mutations in isolates from HBV-monoinfected and HBV-HIV coinfected patients: a 3-yr prospective study. J Clin Virol 2009, 46(4):354-9.
• [20]Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG: The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 1997, 25(24):4876-82.
• [21]Hall T[http://www.mbio.ncsu.edu/BioEdit/bioedit.html] webcite 1999.
• [22]Kumar S, Tamura K, Nei M: MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment. Brief Bioinform 2004, 5:150-63.
• [23]Wang J, Zhou B, Lai Q, Wang Y, Shen G, Wang Z, Chen J, Hou J: Clinical and virological characteristics of chronic hepatitis B with concurrent hepatitis B E antigen and antibody detection. J Viral Hepat 2010, in press.
• [24]Warner N, Locarnini S: The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008, 48(1):88-98.
• [25]Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL: Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001, 34(4 Pt 1):785-791.
• [26]Levine S, Hernandez D, Yamanaka G, Zhang S, Rose R, Weinheimer S, Colonno RJ: Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 2002, 46:2525-2532.
• [27]Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, Carrilho FJ, Omata M: The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001, 107:449-455.
• [28]Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P, Ayres A, Bartholomeusz A, Sievert W, Thompson G, Warner N, Locarnini S, Colonno RJ: Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004, 48:3498-3507.
• [29]Doo E, Liang TJ: Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterology 2001, 120:1000-1008.
• [30]Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, Arnold E: Molecular modelling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 2001, 75:4771-4779.
• [31]Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trépo C, Zoulim F: Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 2007, 46:531-538.
• [32]Leemans WF, Niesters HG, van der Eijk AA, Janssen HL, Schalm SW, de Man RA: Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir. Eur J Gastroenterol Hepatol 2008, 20(8):773-7.
• [33]Sheldon J, Camino N, Rodés B, Bartholomeusz A, Kuiper M, Tacke F, Núñez M, Mauss S, Lutz T, Klausen G, Locarnini S, Soriano V: Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005, 10:727-734.
• [34]Rhee SY, Margeridon-Thermet S, Nguyen MH, Liu TF, Kagan RM, Beggel B, Verheyen J, Kaiser R, Shafer RW: Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery. Antiviral Res 2010, 88(3):269-75.
• [35]Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V: In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 2004, 9:353-363.
• [36]Ying C, De Clercq E, Nicholson W, Furman P, Neyts J: Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepat 2000, 7:161-165.
• [37]Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, Chung YH, Lee YS, Yoo W, Kim SO: Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006, 43:1385-1391.
• [38]Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M: Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007, 133(5):1445-51.
• [39]Gagnieu MC, Barkil ME, Livrozet JM, Cotte L, Miailhes P, Boibieux A, Guitton J, Tod M: Population pharmacokinetics of tenofovir in AIDS patients. J Clin Pharmacol 2008, 48(11):1282-8.